USFDA issues two observations for Lupin Nagpur facility
Mumbai: Lupin has announced the United States Food and Drug Administration (USFDA) has concluded the inspection at the company's Nagpur Oral Solid Dosage Facility with two observations.USFDA inspected the facility from July 3 to July 11, 2023. The inspection closed with issuance of a Form-483 with two observations.An FDA Form 483 is issued to firm management at the conclusion of an...
Mumbai: Lupin has announced the United States Food and Drug Administration (USFDA) has concluded the inspection at the company's Nagpur Oral Solid Dosage Facility with two observations.
An FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.
The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. The company invested 7.9% of its revenue in research and development in FY23.
Lupin has 15 manufacturing sites, 7 research centers, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.
Read also: Lupin Dolutegravir Tablets for Oral Suspension gets tentative USFDA nod for HIV/AIDS
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd